United States · Biotechnology startup
United States · Aligos Therapeutics
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Funding reportedLast round: Post ipo equity
Follow Aligos Therapeutics and see its new rounds in your feed.Start following
What company datasets say Aligos Therapeutics raised
Funding, as reported
Reported in all$401Min dollars
Rounds4
Last roundPost ipo equity
Last round dateOct 2023
Investors listed14
Founders and team
From Aligos Therapeutics's own website: 13 on the team.
- Lawrence M. BlattChairman, President, & Chief Executive Officer
- Rámon PoloSenior Vice President, Head of Global Regulatory Affairs
- Bridget MartellDirector
- Carole NuechterleinDirector
- Heather PrestonDirector
- J.d. M.b.a.Director
- K. Peter HirthDirector
- Margarita ChavezDirector
- David B. SmithTeam
- Julian SymonsTeam
- Lesley Ann CalhounTeam
- Sushmita M. ChandaTeam
- Tse-I LinTeam
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Aligos Therapeutics in front of investors. Or tell us what we have wrong.